International community works together on worldwide isotope shortage

February 17, 2010

Reston, Va.--The medical community has taken additional steps to help alleviate ongoing challenges facing physicians and patients due to the worldwide isotope shortage. SNM cautions that while this is good news, a long-term solution for the U.S. is needed urgently.

Covidien today announced that it has reached an agreement with the Institute of Atomic Energy in Poland (IAE POLATOM) to irradiate targets at the Maria Research Reactor in Poland. It is estimated that these reactors could produce sufficient Molybdenum-99 (Mo-99) to supply up to one million patient doses of Technetium-99m (Tc-99m) within the next six months.

"We are pleased by the level of international cooperation and coordination that is taking place to help resolve some of the continuing challenges that we face due to the ongoing medical isotope shortage," said Michael M. Graham, Ph.D., M.D., president of SNM. "This will help. However, we need to establish a stable source closer to home."

"There may be some short-term improvements for patients in Europe," said Robert W. Atcher, Ph.D., M.B.A, chair of SNM's Domestic Isotope Availability Task Force. "However, this is only a short-term fix to a long-term problem."

There are currently only five major producers of Mo-99--the decay product of which is Tc-99m--in the world, with none in the United States. In the U.S., 16 million diagnostic medical tests are performed annually using Tc-99m to detect cancer, heart disease, thyroid disease and other serious conditions.

"We need a stable Tc-99m supply to diagnose patients in the U.S.," added Graham. "Any and all viable efforts are welcome. Most critically, we must ensure that we have a stable and reliable supply to be able to image patients in the U.S."

The reactor at Petten in the Netherlands is expected to go offline Feb. 19 for a period of four to six months. Compounding problems, the Canadian government recently announced that the AECL reactor in Chalk River will remain offline at least through early April. The AECL reactor has been offline since May 2009 due to significant maintenance issues. Combined, the Petten and AECL reactors supply the U.S. with more than 80 percent of its Mo-99 supply.

Last month, GE-Hitachi and Babcock & Wilcox Technical Services Group announced support from the U.S. Department of Energy's National Nuclear Security Administration (NNSA) for the production of medical isotopes.

On a related note, the American Medical Isotopes Production Act of 2009 (H.R. 3276) was approved by the U.S. House of Representatives in November 2009, but is now held up in the Senate. Graham notes that even if this legislation is passed, a long-term solution is still years away. SNM applauds any and all efforts to expedite Mo-99 production in the U.S. and to provide a reliable isotope supply in the interim.
About SNM--Advancing Molecular Imaging and Therapy

SNM is an international scientific and medical organization dedicated to raising public awareness about what molecular imaging is and how it can help provide patients with the best health care possible. SNM members specialize in molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated.

SNM's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit

Society of Nuclear Medicine

Related Additional Steps Articles from Brightsurf:

Study provides additional support for use of new class of diabetes drugs
A new study led by a cardiologist from Brigham and Women's Hospital has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes to help them control blood sugar levels.

0.5°C of additional warming has a huge effect on global aridity
In a simulation study, UTokyo researchers showed that limiting global warming to 1.5°C rather than 2°C will mitigate aridification in some regions of the world including the Mediterranean, western Europe, and southern Africa.

COVID-19 patients with sleep apnoea could be at additional risk
People who have been diagnosed with obstructive sleep apnoea could be at increased risk of adverse outcomes from COVID-19 according to a new study from the University of Warwick.

Additional data on blood thinner efficacy for COVID-19 and insight on best possible regimens
Mount Sinai study is the basis of a new international clinical trial.

Doctors motivated by both health, malpractice concerns when ordering additional tests
A UCLA-led study has found that dermatopathologists, who specialize in diagnosing skin diseases at the microscopic level, are motivated both by patient safety concerns and by malpractice fears -- often simultaneously -- when ordering multiple tests and obtaining second opinions, with a higher proportion of these doctors reporting patient safety as a concern.

HPV vaccine hesitancy in Japan could result in 5,000 additional death
The precipitous drop in HPV vaccination rates after suspension of proactive recommendations by the government in 2013 could result in an additional 25,000 cervical cancer cases and more than 5,000 additional deaths among females born between 1994 to 2007 in Japan.

Study shows risks for additional procedures after bariatric surgery
Which of the two most common bariatric surgeries -- gastric sleeve or gastric bypass -- has the highest subsequent risk of additional operations or procedures?

An additional component can triple vaccine efficiency, and scientists explained how
A team of Russian scientists carried out a study on the cell immunity level and found out how an adjuvant called azoximer bromide increases the immunogenicity of the anti-flu vaccine.

Additional medications to treat children with JIA are urgently needed
According to new research findings presented this week at the 2019 ACR/ARP Annual Meeting, there is a profound ongoing need for additional medications to control the signs and symptoms of juvenile idiopathic arthritis (JIA), despite the availability of several approved biologic disease-modifying antirheumatic drugs (biologics).

Study predicts modest impact from additional dose of rotavirus vaccine
Giving children an additional dose of rotavirus vaccine when they are nine months old would provide only a modest improvement in the vaccine's effectiveness in low-income countries, according to a new study led by the Yale School of Public Health and the Institute of Infection and Global Health at the University of Liverpool.

Read More: Additional Steps News and Additional Steps Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to